Biotech Firms Begin Developing Measles Treatments Amid Rising US Cases

Measles cases are on the rise in the United States, prompting renewed urgency around treatment options. Biotech companies have begun developing new therapies to address the growing outbreak. The push for treatments is particularly focused on protecting the most vulnerable patients, such as young children and immunocompromised individuals. While vaccination remains the primary defense against measles, the surge in cases has highlighted gaps in treatment options for those who contract the disease.
This is an AI-generated summary. ShortSingh links to the original source for the complete article.


Discussion (0)
Log in to join the discussion and vote.
Log in